

**Press release**

**For immediate release**

## **Genomtec receives the third patent based on the LAMP technique**

*Wroclaw, Poland – 10<sup>th</sup> of May 2021 - Company has been granted a patent protection from the Patent Office of the Republic of Poland for a set of primers amplifying Borrelia burgdorferi's nucleotide sequence , i.e. the bacteria causing Lyme disease. The patent developed by the Genomtec team covers the method of detecting Borrelia burgdorferi, the method of Lyme disease diagnosis, and a diagnostic kit for Lyme disease. It is the second patent granted by the Patent Office of the Republic of Poland and the third patent received by the Company. Currently, Genomtec has got pending twenty patent applications worldwide.*

*The third patent owned by Genomtec increases company's value for investors and confirms the innovativeness and uniqueness of the Genomtec ID solution, which among other infectious pathogens, will be able to detect now Lyme disease utilizing the patented technology. This is a particularly important achievement, because the diagnosis of Lyme disease is not easy due to non-specific systemic symptoms and varied clinical presentation, as well as issues with currently used laboratory diagnostic techniques – said Miron Tokarski, co-founder and CEO of Genomtec.*

Genomtec ID will make possible to diagnose Lyme disease in several minutes during one medical appointment, including at the emergency department, in an ambulance or even in a pharmacy, providing a breakthrough diagnostics so much needed for an early intervention in diseased patients, who nowadays often must wait for many months for diagnostic confirmation, sometimes even leading to a spinal puncture to collect spinal fluid for examination.

The Company plans to manufacture several diagnostic panels, including one that will simultaneously diagnose Lyme disease, MRSA – methicillin-resistant staphylococcus aureus and the bacterial meningitis. These are very severe diseases, sometimes giving similar clinical symptoms, where proper and quick diagnosis initiates targeted treatment determining patient's healthcare outcomes.

*Patent protection of the technology or processes constituting the given technology is a key area of building and safeguarding the intellectual value developed by our Company. Genomtec's technology is being ringfenced by securing ever-increasing number of patents and patent applications for the Genomtec ID diagnostic platform as well as in the space of molecular biology – CEO added.*

Genomtec's flagship solution - the Genomtec ID is a mobile diagnostic system employing microfluidic system and the proprietary, patented SNAAT® technology. This innovative



diagnostic system will be able to carry out several tests from one sample simultaneously, including causal determination of respiratory tract infections or sexually transmitted diseases, even in 15 minutes. Genomtec ID will be used for point of care diagnostics, i.e., in doctor's offices, emergency department, and even a pharmacy.

**Additional information available at:**

Genomtec S.A.  
Magdalena Kicińska  
+48 604 201 230  
[m.kicinska@genomtec.com](mailto:m.kicinska@genomtec.com)

Genomtec SA  
Charles Winiarski  
+44 7972 406 384  
[bkc.winiarski@genomtec.com](mailto:bkc.winiarski@genomtec.com)

**About Genomtec S.A.**

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent-protected SNAAT<sup>®</sup> isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec<sup>®</sup> SARS-CoV-2 EvaGreen<sup>®</sup> laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. The seat of Genomtec SA is located in Wrocław.

More information: [www.genomtec.com](http://www.genomtec.com)